These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23251010)

  • 1. Tolerability and activity of trastuzumab in elderly patients with HER2-overexpressing metastatic breast cancer.
    Zucchini G; Bernardi A; Martoni A; Zamagni C
    Ann Oncol; 2013 Jan; 24(1):264-5. PubMed ID: 23251010
    [No Abstract]   [Full Text] [Related]  

  • 2. Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer.
    Arteaga CL
    Breast Cancer Res; 2003; 5(2):96-100. PubMed ID: 12631388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PF-05280014: A Trastuzumab Biosimilar.
    Paik J
    BioDrugs; 2018 Oct; 32(5):515-518. PubMed ID: 30280367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
    Tokuda Y; Suzuki Y; Saito Y; Umemura S
    Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted anti-HER2 cancer therapy in elderly women diagnosed with breast cancer.
    Molina-Garrido MJ; Guillen-Ponce C; Mora-Rufete A
    Anticancer Agents Med Chem; 2014 Jun; 14(5):639-45. PubMed ID: 23438846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
    Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
    Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.
    Del Mastro L; Lambertini M; Bighin C; Levaggi A; D'Alonzo A; Giraudi S; Pronzato P
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1391-405. PubMed ID: 23072512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2013 Sep; 55(1424):75-6. PubMed ID: 24043217
    [No Abstract]   [Full Text] [Related]  

  • 9. Trastuzumab in metastatic breast cancer.
    Tomao F; Miele E; Spinelli GP; Russillo M; La Ferla G; Tomao S
    Eur J Gynaecol Oncol; 2006; 27(3):247-9. PubMed ID: 16800251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
    Huang Y; Fu P; Fan W
    Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM; Boster BL; Barnett CM
    J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
    Martínez MT; Pérez-Fidalgo JA; Martín-Martorell P; Cejalvo JM; Pons V; Bermejo B; Martín M; Albanell J; Lluch A
    Crit Rev Oncol Hematol; 2016 Jan; 97():96-106. PubMed ID: 26318092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registry.
    Witzel I; Müller V; Abenhardt W; Kaufmann M; Schoenegg W; Schneeweis A; Jänicke F
    BMC Cancer; 2014 Nov; 14():806. PubMed ID: 25371387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of irinotecan hydrochloride (CPT-11) and trastuzumab combination therapy as salvage treatment in patients with HER2 overexpressing metastatic breast cancer].
    Ikeda M; Kurebayashi J; Sonoo H; Oota Y; Fujii S; Shimo T; Miyake A; Seki M; Souda M; Nomura T; Yamamoto Y; Shiiki S; Nakashima K; Tanaka K
    Gan To Kagaku Ryoho; 2009 May; 36(5):773-7. PubMed ID: 19461176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.
    Haddley K
    Drugs Today (Barc); 2013 Nov; 49(11):701-15. PubMed ID: 24308017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab in advanced breast cancer--a decade of experience in Germany.
    Jackisch C; Schoenegg W; Reichert D; Welslau M; Selbach J; Harich HD; Tesch H; Wohlfarth T; Eustermann H; Hinke A
    BMC Cancer; 2014 Dec; 14():924. PubMed ID: 25487774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
    Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
    J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
    Láng I; Bell R; Feng FY; Lopez RI; Jassem J; Semiglazov V; Al-Sakaff N; Heinzmann D; Chang J
    Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.